Acurx pharmaceuticals regains compliance with Nasdaq listing rules

NEW YORK - Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a small-cap biotech with a market capitalization of $6.78 million, has regained compliance with Nasdaq’s continued listing requirements, the company announced Wednesday.

The late-stage biopharmaceutical company received notification letters from The Nasdaq Stock Market LLC confirming it now meets the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum stockholders’ equity threshold of $2.5 million under Listing Rule 5550(b)(1). According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.38, indicating sufficient assets to cover short-term obligations.

As a result, Acurx’s common stock will continue to be listed and traded on the Nasdaq Stock Market, according to the company’s press release statement. Despite the compliance achievement, InvestingPro analysis shows the stock has experienced significant volatility, with a 73% decline year-to-date, though analysts maintain price targets ranging from $20 to $165.80.

Acurx focuses on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead product candidate, ibezapolstat for the treatment of C. difficile infection, is Phase 3 ready with international clinical trials planned for next year, subject to financing.

The company’s approach involves developing antibiotic candidates with a Gram-positive selective spectrum that blocks specific bacterial enzymes, inhibiting DNA replication and leading to bacterial cell death.

Acurx’s research pipeline includes antibiotic candidates targeting various Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).

In other recent news, Acurx Pharmaceuticals reported its financial results for the second quarter of 2025, revealing a notable earnings miss. The company’s earnings per share came in at a loss of $1.89, significantly below the forecasted loss of $0.18, resulting in a surprise negative deviation of 950%. Despite this, H.C. Wainwright raised its price target for Acurx Pharmaceuticals to $31 from $8, maintaining a Buy rating on the stock. This adjustment followed the company’s financial results, which also showed $6.1 million in cash at the end of the quarter. These developments highlight the mixed reactions from analysts and investors, as the company navigates its financial challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.